Deep Track Capital, LP holds a diversified book of 62 reported positions worth $4.8B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter Veradermics Inc first appears in 13F filings, a listing rather than a purchase; they opened Alumis Inc and trimmed Axsome Therapeutics Inc. Their largest long position is Guardant Health Inc at 6% of the reported non-option book. They also disclosed $1.3B in put options (a bearish bet), shown separately below and excluded from the non-option book. Cloning the disclosed picks since 2022 would be +113% (+17.9%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 50.8 points over this window.
Growth of $10,000 cloning Deep Track Capital, LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
94% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Deep Track Capital, LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Venrock Adviser, LLC | 11 / 62 | $1.9B |
| Kynam Capital Management, LP | 10 / 62 | $982.9M |
| Superstring Capital Management LP | 9 / 62 | $72.5M |
| Paradigm Biocapital Advisors LP | 10 / 62 | $2.3B |
| Boxer Capital Management, LLC | 14 / 62 | $483.9M |
| Trails Edge Capital Partners, LP | 10 / 62 | $229.3M |
| Exome Asset Management LLC | 14 / 62 | $58.1M |
| Jones Hill Capital LP | 7 / 62 | $167.7M |
Ranked by the share of each fund's own book sitting in the names it shares with Deep Track Capital, LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Guardant Health Inc COM | $308.4M | 3.34M | 6.4% | ▲+19% Added · +538K sh | |
| 2 | Immunovant Inc COM | $286.3M | 11.53M | 5.9% | —Held | |
| 3 | Tarsus Pharmaceuticals Inc COM | $252.5M | 3.60M | 5.2% | ▲+20% Added · +596K sh | |
| 4 | Vaxcyte Inc COM | $249.9M | 4.30M | 5.2% | ▲+7.5% Added · +300K sh | |
| 5 | Structure Therapeutics Inc SPONSORED ADS | $206.3M | 4.28M | 4.3% | ▲+4.1% Added · +168K sh | |
| 6 | Axsome Therapeutics Inc. COM | $185.9M | 1.10M | 3.8% | ▼−4.3% Reduced · −50K sh | |
| 7 | Apellis Pharmaceuticals Inc COM | $182.3M | 4.53M | 3.8% | ▼−42% Reduced · −3.2M sh | |
| 8 | Ocular Therapeutix Inc COM | $166.7M | 19.69M | 3.4% | ▲+144% Added · +11.6M sh | |
| 9 | Vera Therapeutics Inc CL A | $165.2M | 4.11M | 3.4% | ▲+46% Added · +1.3M sh | |
| 10 | Alumis Inc COM | $149.2M | 6.77M | 3.1% | ▲New New position | |
| 11 | Ionis Pharmaceuticals Inc COM | $146.4M | 1.95M | 3.0% | ▲+15% Added · +250K sh | |
| 12 | Nuvalent Inc COM | $141.0M | 1.38M | 2.9% | ▲New New position | |
| 13 | Alkermes PLC SHS | $127.0M | 3.59M | 2.6% | ▲+80% Added · +1.6M sh | |
| 14 | Centessa Pharmaceuticals PLC SPONSORED ADS | $125.4M | 3.16M | 2.6% | ▲+58% Added · +1.2M sh | |
| 15 | Moonlake Immunotherapeutics CLASS A ORD | $119.5M | 6.41M | 2.5% | ▲+39% Added · +1.8M sh | |
| 16 | Maze Therapeutics Inc COM | $103.8M | 3.48M | 2.1% | ▼−18% Reduced · −769K sh | |
| 17 | Oruka Therapeutics Inc COM | $99.8M | 2.03M | 2.1% | ▼−5.9% Reduced · −127K sh | |
| 18 | Nurix Therapeutics Inc COM | $98.4M | 6.35M | 2.0% | ▼−9.8% Reduced · −691K sh | |
| 19 | Genmab A/s SPONSORED ADS | $98.3M | 3.66M | 2.0% | ▲New New position | |
| 20 | Cytokinetics Inc COM NEW | $90.6M | 1.37M | 1.9% | ▼−59% Reduced · −2.0M sh | |
| 21 | Grail Inc COM | $89.0M | 1.72M | 1.8% | ▲+68% Added · +700K sh | |
| 22 | LB Pharmaceuticals Inc COM SHS | $82.7M | 3.35M | 1.7% | —Held | |
| 23 | MBX Biosciences Inc COM | $82.3M | 2.76M | 1.7% | ▼−15% Reduced · −492K sh | |
| 24 | Bicara Therapeutics Inc COM | $80.8M | 4.06M | 1.7% | ▲+55% Added · +1.4M sh | |
| 25 | Compass Pathways PLC SPONSORED ADS | $67.3M | 12.16M | 1.4% | ▲+66% Added · +4.8M sh | |
| 26 | Biomarin Pharmaceutical Inc COM | $65.0M | 1.15M | 1.3% | ▼−50% Reduced · −1.1M sh | |
| 27 | Bridgebio Pharma Inc COM | $62.5M | 841.4K | 1.3% | ▲+3.9% Added · +31K sh | |
| 28 | Immunocore Hldgs PLC ADS | $58.2M | 1.93M | 1.2% | ▼−3.6% Reduced · −72K sh | |
| 29 | Tango Therapeutics Inc COM | $57.5M | 2.75M | 1.2% | ▲+12% Added · +295K sh | |
| 30 | Definium Therapeutics Inc COM SHS | $56.7M | 3.00M | 1.2% | ▲New New position | |
| 31 | Terns Pharmaceuticals Inc COM | $56.6M | 1.07M | 1.2% | ▲+40% Added · +305K sh | |
| 32 | Geron Corp COM | $47.3M | 31.72M | 1.0% | ▼−2.4% Reduced · −791K sh | |
| 33 | Ani Pharmaceuticals Inc COM | $46.1M | 600.0K | 1.0% | ▲+26% Added · +122K sh | |
| 34 | Cormedix Inc COM | $42.6M | 6.27M | 0.9% | ▲+19% Added · +1.0M sh | |
| 35 | Ataibeckley Inc COM SHS | $42.5M | 12.00M | 0.9% | ▲New New position | |
| 36 | Celldex Therapeutics Inc New COM NEW | $40.7M | 1.28M | 0.8% | ▼−32% Reduced · −617K sh | |
| 37 | Cogent Biosciences Inc COM | $38.5M | 1.00M | 0.8% | ▲+121% Added · +547K sh | |
| 38 | Corvus Pharmaceuticals Inc COM | $36.5M | 2.49M | 0.8% | ▲New New position | |
| 39 | Dyne Therapeutics Inc COM | $36.3M | 2.00M | 0.7% | ▼−25% Reduced · −650K sh | |
| 40 | Soleno Therapeutics Inc COM | $36.1M | 1.08M | 0.7% | ▲+7.9% Added · +79K sh | |
| 41 | Aclaris Therapeutics Inc COM | $35.0M | 9.35M | 0.7% | ▲New New position | |
| 42 | Veradermics Inc COMMON STOCK | $31.6M | 500.0K | 0.7% | →Listed Newly reportable | |
| 43 | Verastem Inc COM NEW | $30.4M | 5.74M | 0.6% | —Held | |
| 44 | Engene Holdings Inc COM | $29.8M | 4.38M | 0.6% | —Held | |
| 45 | Viridian Therapeutics Inc COM | $27.3M | 1.39M | 0.6% | ▼−45% Reduced · −1.1M sh | |
| 46 | X4 Pharmaceuticals Inc COM NEW | $26.2M | 6.34M | 0.5% | ▲+26% Added · +1.3M sh | |
| 47 | Solid Biosciences Inc COM NEW | $25.7M | 3.57M | 0.5% | ▲New New position | |
| 48 | Enanta Pharmaceuticals Inc COM | $24.7M | 1.96M | 0.5% | —Held | |
| 49 | Apogee Therapeutics Inc COM | $24.0M | 285.0K | 0.5% | ▲New New position | |
| 50 | Kura Oncology Inc COM | $21.5M | 2.64M | 0.4% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1856083/holdings"
Use Arkolith to show Deep Track Capital, LP's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $1.3B | 10.0M |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the non-option book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 63 | $6.1B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 44d | 55 | $5.6B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 56 | $3.6B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 66 | $3.1B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 45d | 69 | $3.1B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 63 | $2.7B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45d | 71 | $3.2B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 68 | $3.4B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 45d | 66 | $3.5B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 45d | 60 | $3.0B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 45d | 63 | $2.6B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Sep 6, 2023 | 68d | 55 | $2.2B | 13F-HR/A |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 45d | 58 | $2.4B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 45d | 60 | $2.4B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 45d | 65 | $2.2B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 43d | 51 | $1.5B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 46d | 52 | $1.6B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 45d | 55 | $1.4B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.